OVERVIEW
Results from the APHINITY trial showed that in patients with HER2-positive metastatic breast cancer, pertuzumab added to trastuzumab and docetaxel has been shown to significantly prolong both progression-free survival and overall survival.
The APHINITY Trial
APHINITY was a randomised, double-blind, phase III study comparing the addition of pertuzumab or placebo to adjuvant trastuzumab and chemotherapy in patients with HER2-positive early breast cancer.
The APHINITY trial was supported by F. Hoffmann-La Roche Ltd/Genentech and was designed by the Breast International Group (BIG) in collaboration with the sponsor.
The database was maintained at the Institut Jules Bordet Clinical Trials Support Unit (Brussels, Belgium), and the statistical analyses were carried out by Frontier Science Scotland.
TITLE OF PUBLICATION
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
AUTHORS
Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D., Bines, J., Gelber, R., Piccart, M., and Baselga, J. for the APHINITY Steering Committee and Investigators
PUBLICATION REFERENCE
New England Journal of Medicine (NEJM) | Volume 377 | Page(s) 122-131 | 2017
